tbuckley/cabot-search huggingface dataset:
LRRC15 in breast cancer: Description of two transcript isoforms and identification of genotypical polymorphisms in cells lines with different invasion abilities
Authors: Christina Schuetz, Tanja Fehm, Erich Solomayer, Diethelm Wallwiener, Hans Neubauer
Journal: Cancer Research (2007)

2020  Background  A fundamental step during the progression of breast cancer is the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). At this point, cancer cells gain the potential for spreading and metastasis. In a previous microarray analysis we showed that expression of LRRC15 is up-regulated in IDC compared to DCIS (Schuetz et al., Cancer Res. 2006;66:5278-86).  Aim  The aim of this study was to validate LRRC15’s differential expression during tumor progression and to functionally analyse its role in invasive breast cancer cells.  Methods  Three different breast epithelial cell lines with described differences in their abilitiy to form tumors and to invade surrounding tissue (MCF10A, MCF7, and MDA-MB-231) were analysed for the expression level of LRRC15. Full length cDNAs were synthesized from MCF10A and MDA-MB-231 cells and analysed for single nucleotide polymorphisms (SNPs). The expression pattern of two LRRC15 isoforms was investigated by RT-PCR in normal versus matched cancer tissue and between different invasive breast tumors, respectively.  Results  The expression of LRRC15 was highly up-regulated in invasive MDA-MB-231 cells. Sequencing of different cDNA clones provided ten SNPs throughout the open reading frame between non-invasive MCF10A and highly invasive MDA-MB-231 cells. Two SNPs cause amino acid changes at positions 264 and 286 in the predicted protein sequence of LRRC15 in MDA-MB-231 cells. MCF10A and MDA-MB-231 cells are homozygous carriers of the two respective polymorphisms. Additionally, the differential expression pattern of two LRRC15 transcript variants in normal versus matched cancer tissue and between different invasive breast tumors was verified. The larger isoform contains an alternative start codon (ATG) which alters the N-terminal signaling peptide of LRRC15 protein.  >Conclusion  >Our data show that LRRC15 is not only differentially expressed between DCIS and IDC but is also expressed in different isoforms. Differences in the amino acid sequence might change its role in the process of tumor cell invasion. Therefore, LRRC15 might be a potential prevention target for future therapeutic regimes.
P2.03a-045 Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Authors: Óscar Juan, Francisco Aparisi, Mar Llorente, Bartomeu Massuti, Alfredo Sanchez-Hernandez, María Martín, Sara Blasco Cordellat, Ana Blasco, Regina Gironés
Journal: Journal of Thoracic Oncology (2017)
Endoscopic sleeve gastroplasty using Apollo Overstitch as a bridging procedure for superobese and high risk patients
Authors: Ricardo Zorron, Wilfried Veltzke-Schlieker, Andreas Adler, Christian Denecke, Tomasz Dziodzio, Johann Pratschke, Christian Benzing
Journal: Endoscopy (2017)

In some cases, bariatric procedures cannot be performed via laparoscopic or open surgery because of surgical contraindications or high operative risk. Endoscopic sleeve gastroplasty (ESG) using an Overstitch (Apollo Endosurgery, Austin, Texas, USA) is a recently described procedure [1] [2] with good preliminary 1-year results in small series and low complication rates [3] [4] [5] for patients with a body mass index (BMI) ranging from 30 – 45 kg/m2. However, the routine use of ESG for superobese and high risk patients has not yet been described.
Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting “Trojan Horse” Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance
Authors: Kai Shi, Jianxiu Xue, Yan Fang, Hongshu Bi, Shan Gao, Dongjuan Yang, Anqi Lu, Yuai Li, Yao Chen, Liyuan Ke
Journal: Theranostics (2017)

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in a variety of tumor cells, but not most normal cells. Nevertheless, its therapeutic potential is limited due to the frequent occurrence of resistance in tumor cells, especially hepatocellular carcinoma cell lines. Therefore, we investigated the reversal effect of STAT3-decoy oligonucleotides (ODNs) on TRAIL resistance. Methods. Considering that the drawback of poor cellular permeability and rapid degradation in vivo limited ODNs' further clinical applications, we developed a biomimetic calcium phosphate-reconstituted low density lipoprotein nanovehicle (CaP@LDL) that would serve as a "Trojan horse" to carry STAT3-decoy ODNs into tumor cells and then regulate TRAIL-induced apoptosis. Results. In comparison with native ODNs, the reconstituted CaP@LDL packaged ODNs showed significantly increased serum stability, cellular transfection, in vitro synergistic cytotoxicity and apoptosis in hepatoma cells, while there was no cytotoxicity to normal cells. The improved TRAIL sensitization is attributed to blocking of STAT3 signaling and consequent expression of the downstream target antiapoptotic gene. Following systemic administration, CaP@LDL displayed LDL-mimicking pharmacokinetic behavior such as attenuated blood clearance as well as enhanced accumulation in tumor and hepatorenal sites. With the synergistic combination of decoyODN/CaP@LDL, TRAIL dramatically inhibited hepatic tumor growth in a xenograft model and induced significant tumor apoptosis in vivo. Conclusion. These results suggested that CaP@LDL-mediated STAT3-decoy ODN delivery might be a promising new strategy for reversing TRAIL resistance in hepatocellular carcinoma therapy.
TCT-44 Frequency and Impact of Acute Stent Deformation After PCI of Left Main Coronary Artery Disease: An EXCEL trial intravascular ultrasound substudy
Authors: Song-Yi Kim, Akiko Maehara, Bela Merkely, Imre Ungi, Ad Van Boven, Erick Schampaert, Roxana Mehran, Ori Ben-Yehuda, Ovidiu Dressler, A. Pieter Kappetein, Joseph Sabik, Patrick Serruys, Gary Mintz, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Stress and skin disease quality of life: the moderating role of anxiety sensitivity social concerns
Authors: L.J. Dixon, S.M. Witcraft, N.K. McCowan, R.T. Brodell
Journal: British Journal of Dermatology (2017)

Stress is an important factor in the onset, exacerbation and reoccurrence of many skin diseases. Little is known about psychological risk factors that affect the association between stress and dermatological conditions. One relevant factor that may modulate this link is anxiety sensitivity (AS) social concerns - the propensity to respond fearfully to anxiety-related sensations (e.g. sweating, flushing) owing to perceived social consequences (e.g. rejection or humiliation).To gain insight into psychological factors affecting skin disease, we examined the moderating role of AS social concerns in the relationship between stress and skin disease quality of life (QoL).Participants [n = 237 (161 female), mean ± SD age 34·18 ± 9·57 years] with active skin disease symptoms were recruited online and completed questionnaires assessing stress, AS social concerns, skin disease QoL and global skin disease symptom severity.AS social concerns moderated the association between stress and skin-related emotional and social functioning in adults with skin disease. Stress was a significant predictor of the impairment associated with skin disease.Stress was linked to skin disease-related emotional and functional impairment associated with skin disease among individuals with high AS social concerns. These results highlight the potential for AS reduction interventions to break the vicious cycle of stress and skin disease symptoms and to improve psychosocial well-being in dermatology patients.
A molecular basis of human T cell receptor autoreactivity toward self-phospholipids
Authors: Adam Shahine, Ildiko Van Rhijn, Tan-Yun Cheng, Sarah Iwany, Stephanie Gras, D. Branch Moody, Jamie Rossjohn
Journal: Science Immunology (2017)

Structure of autoreactive CD1b-restricted T cell receptor (TCR) provides insights into lipid autoreactivity of TCRs.
A Laser-Activated Biocompatible Theranostic Nanoagent for Targeted Multimodal Imaging and Photothermal Therapy
Authors: Liming Deng, Xiaojun Cai, Danli Sheng, Yang Yang, Eric M. Strohm, Zhigang Wang, Haitao Ran, Dong Wang, Yuanyi Zheng, Pan Li, Tingting Shang, Yi Ling, Fengjuan Wang, Yang Sun
Journal: Theranostics (2017)

Multifunctional nanoparticles have been reported for cancer detection and treatment currently.However, the accurate diagnosis and efficient treatment for tumors are still not satisfied.Here we report on the development of targeted phase change multimodal polymeric nanoparticles for the imaging and treatment of HER2-positive breast cancer.Methods: We evaluated the multimodal imaging capabilities of the prepared nanoparticles in vitro using agar-based phantoms.The targeting performance and cytotoxicity of the nanoparticles were examined in cell culture using SKBR3 (over-expressing HER2) and MDA-MB-231 (HER2 negative) cells.We then tested the magnetic resonance (MR)/ photoacoustic (PA)/ ultrasound (US)/ near-infrared fluorescence (NIRF) multimodal imaging properties and photothermal effect of the nanoparticles in vivo using a SKBR3 breast xenograft model in nude mice.Tissue histopathology and immunofluorescence were also conducted.Results: Both in vitro and in vivo systematical studies validated that the hybrid nanoparticles can be used as a superb MR/US/PA/NIRF contrast agent to simultaneously diagnose and guide tumor photothermal therapy (PTT).When irradiated by a near infrared laser, the liquid PFP vaporizes to a gas, rapidly expelling the contents and damaging surrounding tissues.The resulting micro-sized bubbles provide treatment validation through ultrasound imaging.Localization of DIR and SPIO in the tumor region facilitate photothermal therapy for targeted tumor destruction.The mice treated with HER2 targeted nanoparticles had a nearly complete response to treatment, while the controls showed continued tumor growth.Conclusion: This novel theranostic agent may provide better diagnostic imaging and therapeutic potential than current methods for treating HER2-positive breast cancer.
Optimizing the Clinical Care of Lesbian, Gay, Bisexual, and Transgender Older Adults
Authors: Alexia M. Torke, Jennifer L. Carnahan
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Agrupaciones de casos de legionelosis asociadas con viajar a España durante el periodo Enero 2001-Julio 2003
Authors: R Cano, N Prieto, C Martin, C Pelaz, S Mateo
Journal: Eurosurveillance (2004)

La vigilancia epidemiologica y el control de la legionelosis asociada a viajes son actividades necesarias en terminos de salud publica y para ello es necesaria la colaboracion entre paises. Dentro del marco de la red EWGLINET, fueron elaboradas recomendaciones europeas sobre el control y la prevencion de la legionelosis asociada a los viajes. Se han especificado los criterios de notificacion y de respuesta cuando aparecen casos o agrupaciones. Este articulo presenta el analisis de los datos correspondientes a las 46 agrupaciones relacionadas con viajes a Espana entre enero de 2001 y julio de 2003.
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Authors: Evangelos D. Michelakis, Vikram Gurtu, Linda Webster, Gareth Barnes, Geoffrey Watson, Luke Howard, John Cupitt, Ian Paterson, Richard B. Thompson, Kelvin Chow, Declan P. O’Regan, Lan Zhao, John Wharton, David G. Kiely, Adam Kinnaird, Aristeidis E. Boukouris, Chris White, Jayan Nagendran, Darren H. Freed, Stephen J. Wort, J. Simon R. Gibbs, Martin R. Wilkins
Journal: Science Translational Medicine (2017)

Metabolic modulation with dichloroacetate improves hemodynamics in genetically susceptible patients with idiopathic pulmonary arterial hypertension.
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Authors: T. Zuberbier, R. Asero, C. Bindslev‐Jensen, G. Walter Canonica, M. K. Church, A. M. Giménez‐Arnau, C. E. H. Grattan, A. Kapp, M. Maurer, H. F. Merk, B. Rogala, S. Saini, M. Sánchez‐Borges, P. Schmid‐Grendelmeier, H. Schünemann, P. Staubach, G. A. Vena, B. Wedi
Journal: Allergy (2009)

This guideline, together with its sister guideline on the classification of urticaria (Zuberbier T, Asero R, Bindslev‐Jensen C, Canonica GW, Church MK, Giménez‐Arnau AM et al. EAACI/GA²LEN/EDF/WAO Guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64 : 1417–1426), is the result of a consensus reached during a panel discussion at the Third International Consensus Meeting on Urticaria, Urticaria 2008 , a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU‐funded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO). As members of the panel, the authors had prepared their suggestions regarding management of urticaria before the meeting. The draft of the guideline took into account all available evidence in the literature (including Medline and Embase searches and hand searches of abstracts at international allergy congresses in 2004–2008) and was based on the existing consensus reports of the first and the second symposia in 2000 and 2004. These suggestions were then discussed in detail among the panel members and with the over 200 international specialists of the meeting to achieve a consensus using a simple voting system where appropriate. Urticaria has a profound impact on the quality of life and effective treatment is, therefore, required. The recommended first line treatment is new generation, nonsedating H 1 ‐antihistamines. If standard dosing is not effective, increasing the dosage up to four‐fold is recommended. For patients who do not respond to a four‐fold increase in dosage of nonsedating H 1 ‐antihistamines, it is recommended that second‐line therapies should be added to the antihistamine treatment. In the choice of second‐line treatment, both their costs and risk/benefit profiles are most important to consider. Corticosteroids are not recommended for long‐term treatment due to their unavoidable severe adverse effects. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).
TCT-448 Transcatheter aortic valve replacement for isolated severe native aortic valve regurgitation – results from the TAVR-NAVR Registry
Authors: Ole De Backer, Thomas Pilgrim, Lars Sondergaard, Matheus Simonato dos Santos, G. Burkhard Mackensen, Alfredo Cerillo, Joachim Schofer, Nicolas Amabile, Guy Achkouty, Ulrich Schäfer, Marcus-André Deutsch, Jan-Malte Sinning, David Hildick-Smith, Nicolas Van Mieghem, Stephan Windecker, Won Kim, Thierry Lefevre, Moritz Seiffert, Sabine Bleiziffer, Anna Sonia Petronio, Maurizio Taramasso, Azeem Latib, Danny Dvir
Journal: Journal of the American College of Cardiology (2017)
P2.13-021 Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals
Authors: B. Mccall, C. Wilshire, C. Fuller, C. Gilbert, J. Fathi, J. Handy, K. Costas, B. Louie, R. Aye, A. Farivar, E. Vallieres, J. Gorden
Journal: Journal of Thoracic Oncology (2017)
Is humility a sentiment?
Authors: Aaron C Weidman, Jessica L Tracy
Journal: Behavioral and Brain Sciences (2017)

Abstract Gervais &amp; Fessler reintroduce the concept of a sentiment as a framework for conceptualizing contempt, a construct with both attitudinal and emotional components. We propose that humility might also fit this mold. We review recent findings regarding the antecedents, phenomenology, and functional consequences of humility, and discuss why conceptualizing it as a sentiment may advance our understanding of this construct.
A malária importada na Alemanha, em 1996
Authors: L Apitzsch, Gernot Rasch, W Kiehl
Journal: Eurosurveillance (1998)

A malaria nao e endemica na Alemanha, mas representa uma das mais frequentes doencas infecciosas importadas. O numero de casos importados aumentou de 1994 a 1996 (figura 1) (1-4); em 1997, de acordo com dados preliminares, houve um total de 994 casos. Em 1996, foram notificadas na Alemanha, 1021 casos de malaria (1,25 casos por 100 000 habitantes) representando um aumento global de 9% em relacao a 1995. Este aumento foi particularmente pronunciado durante o segundo e terceiro trimestre de 1996. As maiores taxas de incidencia, em 1996, foram observadas em Berlim (121 casos; 3,49/100000) e em Hamburgo (93 casos; 5,44/l00 000). Em Hamburgo, mais de 60% dos casos foram de residentes nao-alemaes regressando de uma viagem internacional.
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Authors: Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O’Neil, Patrick A. Ott, Sarina A. Piha-Paul, Carlos Gomez-Roca, Emilie M.J. van Brummelen, Hope S. Rugo, Shari Thomas, Sanatan Saraf, Reshma Rangwala, Andrea Varga
Journal: Journal of Clinical Oncology (2017)

Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, by investigator review. Safety was a secondary end point. Results Twenty-four patients were enrolled in the cervical cancer cohort. The median age was 42 years (range, 26 to 62 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received two or more lines of therapy, including bevacizumab (10 of 24 patients), for advanced disease. At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 months). Overall response rate was 17% (95% CI, 5% to 37%); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable disease. Median duration of response for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months). Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in ≥ 10% of patients. Five patients experienced grade 3 treatment-related AEs. No grade 4 treatment-related AEs or deaths were observed. Conclusion In patients with programmed death ligand 1–positive advanced cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consistent with that seen in other tumor types.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Authors: Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir R. Aref, Elena Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John E. Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Yanxi Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray, Kwok-Kin Wong
Journal: Cancer Discovery (2017)

Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function. Although CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration and activation of effector T cells. Moreover, CDK4/6 inhibition augments the response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture system and in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies.Significance: Our results define previously unrecognized immunomodulatory functions of CDK4/6 and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may increase treatment efficacy in patients. Furthermore, our study highlights the critical importance of identifying complementary strategies to improve the efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 216-33. ©2017 AACR.See related commentary by Balko and Sosman, p. 143See related article by Jenkins et al., p. 196This article is highlighted in the In This Issue feature, p. 127.
TCT-845 Two-Year Longitudinal Evaluation of a Second-Generation Thin-Strut Sirolimus-Eluting Bioresorbable Coronary Scaffold with Hybrid Cell Design in Porcine Coronary Arteries
Authors: Pawel Gasior, Yanping Cheng, Jinggang Xia, Gerard Conditt, Jenn McGregor, Renu Virmani, Juan Granada, Greg Kaluza
Journal: Journal of the American College of Cardiology (2017)